Contribute Try STAT+ Today

Monica Coenraads’ daughter has never spoken since she blurted out “duck!” while taking a bath soon before her first birthday, and has never walked. Chelsea lost the ability to hold her sippy cup and stopped responding when Coenraads played “can you touch your nose?” She cannot use her hands, and must be fed through a tube, all of which is tragically standard for girls with severe Rett syndrome, a brain disorder that usually strikes during toddlerhood and is caused by a genetic mutation.

It may seem unlikely, then, that such a devastating condition is near the front of the line of brain disorders that scientists believe might one day be treated with genome editing technologies such as CRISPR. By “treated,” they don’t mean just keeping a disease from getting worse. They mean reversing the damage and giving the brain a second chance: CRISPR would penetrate the brain of a patient who has lived with a disorder for years and repair the mutation that caused it, unleashing the brain’s capacity of neuroplasticity to weave new circuitry, grow new neurons, or otherwise do right what it did wrong when the mutant gene called the shots.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Humbly, where could I join a CRISPR outreach program linked to brain disease? Humbly, could STAT help sponsor summer 2018 US Nobel Prize seminars? Humbly, I would love to be invited.

  • Dear professor,

    Thank you for your review about XLID , the genetic origin of epileptic encephalopathies is currently being met more frequently after the progress in the whole exome sequence test . One of these Monogenic mutations is the iqsec2 mutation which accounts for nearly 10% of children referred to the genetic tests for intractable seizures; regarding that the technology in diagnosis is more or less recent, and children affected are usually misdiagnosed and managed as being on the autism spectrum disorder, many aspects of the pathology is still not sufficiently adressed leaving those children and their families suffering. It seems that gene therapy, although a kind of future possibility,is the greatest hope for these affected groups. My inquiry is about the future possibility of using the CRISPR technology to introduce a nonpathogenic copy of the gene and the how to establish a link between affected families and research institutions to fasten the progress in this field. 

    Kindly accept my best regards

  • Humbly, you cite a U Cal Berkeley professor. I can ask to interview with the staff. Humbly, please inform me about MIT contact offices as well.
    [email protected]

Comments are closed.